Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 114 Published: December 30, 2021 Report Code: GMDGDHC13193IDB

Influenza A Virus, H7N9 Subtype Infections pipeline market research report provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects.

Which are the key targets in the Influenza A Virus, H7N9 Subtype Infections pipeline market?

The key targets in the Influenza A Virus, H7N9 Subtype Infections pipeline market are Hemagglutinin, Exo Alpha Sialidase, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Neuraminidase A, Polymerase Basic Protein 2, RNA Polymerase, and Substance P Receptor. Hemagglutinin has the highest number of pipeline products in the Influenza A Virus, H7N9 Subtype Infections pipeline market.

Influenza A Virus, H7N9 Subtype Infections pipeline market, by targets

Influenza A Virus, H7N9 Subtype Infections pipeline market, by targets

For more target insights, download a free report sample

Which are the key MoA in the Influenza A Virus, H7N9 Subtype Infections pipeline market?

The key MoA in the Influenza A Virus, H7N9 Subtype Infections pipeline market are Exo Alpha Sialidase Inhibitor, Hemagglutinin Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Neuraminidase A Inhibitor, Polymerase Basic Protein 2 Inhibitor, RNA Polymerase Inhibitor, and Substance P Receptor Agonist.

Influenza A Virus, H7N9 Subtype Infections pipeline market, by MoA

Influenza A Virus, H7N9 Subtype Infections pipeline market, by MoA

For more MoA insights, download a free report sample

Which are the key RoA in the Influenza A Virus, H7N9 Subtype Infections pipeline market?

The key RoA in the Influenza A Virus, H7N9 Subtype Infections pipeline market are Intramuscular, Parenteral, Oral, Nasal, Inhalational, Intralesional, and Intravenous. Intramuscular has the highest number of pipeline products in the Influenza A Virus, H7N9 Subtype Infections pipeline market.

Influenza A Virus, H7N9 Subtype Infections pipeline market, by RoA

Influenza A Virus, H7N9 Subtype Infections pipeline market, by RoA

For more RoA insights, download a free report sample

Which are the key molecule type in the Influenza A Virus, H7N9 Subtype Infections pipeline market?

The key molecule type in the Influenza A Virus, H7N9 Subtype Infections pipeline market are Inactivated Vaccine, Small Molecule, DNA Vaccine, Live Attenuated Vaccine, Subunit Vaccine, Vaccine, mRNA Vaccine, Recombinant Protein, and Antisense RNAi Oligonucleotide. Inactivated Vaccine has the highest number of pipeline products in the Influenza A Virus, H7N9 Subtype Infections pipeline market.

Influenza A Virus, H7N9 Subtype Infections pipeline market, by molecule type

Influenza A Virus, H7N9 Subtype Infections pipeline market, by molecule type

For more molecule type insights, download a free report sample

Which are the key companies in the Influenza A Virus, H7N9 Subtype Infections pipeline market?

The key companies in the Influenza A Virus, H7N9 Subtype Infections pipeline market are Hualan Biological Bacterin Co Ltd, NanoViricides Inc, AIM ImmunoTech Inc, AusBio Ltd, Beijing Tiantan Biological Products Co Ltd, Cocrystal Pharma Inc, Codagenix Inc, CSL Ltd, EpiVax Inc, GlaxoSmithKline Plc, Greffex Inc, and Inovio Pharmaceuticals Inc. Hualan Biological Bacterin Co Ltd has the highest number of pipeline products.

Influenza A Virus, H7N9 Subtype Infections pipeline market, by companies

Influenza A Virus, H7N9 Subtype Infections pipeline market, by companies

To know more about companies, download a free report sample

Market report overview

Key targets Hemagglutinin, Exo Alpha Sialidase, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Neuraminidase A, Polymerase Basic Protein 2, RNA Polymerase, and Substance P Receptor
Key MoA Exo Alpha Sialidase Inhibitor, Hemagglutinin Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Neuraminidase A Inhibitor, Polymerase Basic Protein 2 Inhibitor, RNA Polymerase Inhibitor, and Substance P Receptor Agonist
Key RoA Intramuscular, Parenteral, Oral, Nasal, Inhalational, Intralesional, and Intravenous
Key molecule type Inactivated Vaccine, Small Molecule, DNA Vaccine, Live Attenuated Vaccine, Subunit Vaccine, Vaccine, mRNA Vaccine, Recombinant Protein, and Antisense RNAi Oligonucleotide
Key companies Hualan Biological Bacterin Co Ltd, NanoViricides Inc, AIM ImmunoTech Inc, AusBio Ltd, Beijing Tiantan Biological Products Co Ltd, Cocrystal Pharma Inc, Codagenix Inc, CSL Ltd, EpiVax Inc, GlaxoSmithKline Plc, Greffex Inc, and Inovio Pharmaceuticals Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections
  • The report reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Influenza A Virus, H7N9 Subtype Infections therapeutics and enlists all their major and minor projects
  • The report assesses Influenza A Virus, H7N9 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Players

  • AIM ImmunoTech Inc

    AusBio Ltd

    Beijing Tiantan Biological Products Co Ltd

    Cocrystal Pharma Inc

    Codagenix Inc

    CSL Ltd

    EpiVax Inc

    GlaxoSmithKline Plc

    Greffex Inc

    Hualan Biological Bacterin Co Ltd

    Inovio Pharmaceuticals Inc

    Medicago Inc

    Medigen Vaccine Biologics Corp

    Moderna Inc

    NanoViricides Inc

    New Amsterdam Sciences Inc

    Ology Bioservices Inc

    Pneumagen Ltd

    Sanofi

    Seqirus Ltd

    Shanghai Institute of Biological Products Co Ltd

    Shionogi & Co Ltd

    Virion Biotherapeutics (Inactive)

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H7N9 Subtype Infections – Overview

Influenza A Virus, H7N9 Subtype Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H7N9 Subtype Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H7N9 Subtype Infections – Companies Involved in Therapeutics Development

Influenza A Virus, H7N9 Subtype Infections – Drug Profiles

Influenza A Virus, H7N9 Subtype Infections – Dormant Projects

Influenza A Virus, H7N9 Subtype Infections – Discontinued Products

Influenza A Virus, H7N9 Subtype Infections – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by AIM ImmunoTech Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by AusBio Ltd, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Beijing Tiantan Biological Products Co Ltd, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Cocrystal Pharma Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Codagenix Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by CSL Ltd, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by EpiVax Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by GlaxoSmithKline Plc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Greffex Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Hualan Biological Bacterin Co Ltd, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Medicago Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Medigen Vaccine Biologics Corp, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Moderna Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by NanoViricides Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by New Amsterdam Sciences Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Ology Bioservices Inc, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Pneumagen Ltd, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Sanofi, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Seqirus Ltd, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Shanghai Institute of Biological Products Co Ltd, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Shionogi & Co Ltd, 2021

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Virion Biotherapeutics (Inactive), 2021

Influenza A Virus, H7N9 Subtype Infections – Dormant Projects, 2021

Influenza A Virus, H7N9 Subtype Infections – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.